We previously reported a highly selective PROTAC degrader targeting both mSWI/SNF ATPase subunits, SMARCA2 and SMARCA4, demonstrating remarkable therapeutic efficacy in various preclinical models of advanced prostate cancer through intravenous administration (16). The gene discussed is SMARCA2; the disease is prostate cancer.